Compare AbCellera Biologics Inc (ABCL) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? AbCellera Biologics Inc trades at $9.92 (market cap $2.99B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.23. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | LQD | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | — |
52-Week High | $9.76 | $112.91 |
52-Week Low | $2.78 | $105.96 |
Enterprise Value | $2.58B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
LQD, the iShares iBoxx $ Investment Grade Corporate Bond ETF, trades at $106.335, up 0.35% today, while technical indicators signal a bearish trend with moving averages and key oscillators in sell or neutral territory. The ETF has declared several dividends for 2026, with payments scheduled through August, reflecting its income-focused strategy amid fluctuating bond markets driven by inflation fears and geopolitical tensions.
The outlook for LQD is cautious due to bearish technicals and macroeconomic pressures like rising oil prices and potential Fed rate hikes, which could pressure corporate bond yields. Investors may find value in its investment-grade corporate debt exposure for diversification, but must monitor interest rate volatility and economic data closely for risks to fixed income returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
